ABSTRACT
Molecular analysis of 17 genomically unrelated clinical VanB-type vancomycin-resistant enterococcus isolates from hospital patients in Germany, Norway, Sweden, the United Kingdom and the United States revealed three subtypes of the vanB gene cluster—vanB1, vanB2, andvanB3—which was in accordance with previous subtyping of the ligase gene sequence. There was no correlation betweenvanB subtype and levels of vancomycin resistance. All strains studied carried a structurally conserved vanB gene cluster as shown by long-range PCR (long PCR) covering 5,959 bp of the published sequence in vanB1 strain V583. Restriction analysis of long PCR amplicons displayed one unique vanB1pattern and a second vanB2- and vanB3-specific pattern. The vanSB-vanYB intergenic sequences with flanking coding regions were identical within eachvanB subtype with one exception. A U.S. vanB2isolate had a 789-bp enlargement of this region containing a putative open reading frame (ORF) with substantial homology to an ORF in theClostridium perfringens IS1469 insertion element. The molecular heterogeneity within the vanB gene cluster has implications for the selection of PCR primers, as the primers must ensure detection of all vanB subtypes, and is of importance when considering reservoirs and dissemination ofvanB resistance. The molecular identity within thevanB1 and the vanB2 subtype indicates horizontal transmission of both gene clusters between isolates in different geographical areas. Restriction analysis of long PCRvanB amplicons may reveal specific varieties that can be used as epidemiological markers for mobile determinants conferring VanB-type resistance. The finding of three distinct vanBgene clusters should encourage a search for different environmental reservoirs of vanB resistance determinants.
Glycopeptide resistance in enterococci is phenotypically and genotypically heterogeneous. The VanA and the VanB types are the most commonly encountered forms of acquired glycopeptide resistance (1, 24) and have the same basic mechanism of resistance (8). VanA-type strains show inducible resistance to high levels of vancomycin and moderate to high levels of teicoplanin. The vanA gene cluster is located on transposon Tn1546 or related elements and can be part of the chromosome, on nonconjugative or conjugative plasmids (14, 15). The VanB phenotype, mediated by the vanB gene cluster (see Fig. 3) (8-10), is characterized by inducible resistance to various levels of vancomycin and susceptibility to teicoplanin (25). The vanB gene cluster can reside on a composite transposon, Tn1547, but is not always linked to IS16- or IS256-like elements, which characterize Tn1547 (24). A novel chromosomalvanB-containing transposon (Tn5382) was recently described in clonally distinct U.S. Enterococcus faeciumstrains (5, 16). Dissemination of VanB-type resistance among enterococci results from conjugation of plasmids (2, 30) or large chromosomal elements ranging from 90 to 250 kb in size (5, 23).
Recent reports (12, 22) have shown DNA sequence heterogeneity suggesting three subtypes of the vanB ligase gene: vanB1, vanB2, and vanB3. ThevanB1 gene has previously been designated vanB(6, 10, 12, 22). However, to our knowledge potential differences in the organization and structure of the vanBgene clusters in genomically diverse vancomycin-resistant enterococcus (VRE) strains have not been examined extensively.
Possible mechanisms for the spread of vanB-possessing VRE include both horizontal transfer of the vancomycin resistance genes as well as clonal dissemination of strains. Epidemiological studies of VRE should therefore apply total bacterial DNA analysis as well as molecular characterization of mobile resistance determinants. We have developed a long-range PCR (long PCR) for the structural analysis ofvanB gene clusters in VRE, Tn1547 PCR (13). The designation Tn1547 PCR may, however, not be very accurate, as this PCR covers the vanB gene cluster and cannot be used to determine if the cluster is located on the Tn1547 transposon or other mobile DNA elements (5). In the present work we have renamed this PCRvanB long PCR. The objective of the present study was to characterize the vanB gene cluster of genomically unrelated VRE isolates from European countries and the United States. The strains were examined by restriction fragment length pattern (RFLP) analysis of long PCR amplicons and DNA sequencing of thevanSB-vanYB intergenic region as well as part of the vanB gene.
MATERIALS AND METHODS
Bacterial strains.The VanB strains used in this study are listed in Table 1. E. faecalisATCC 29212, E. faecium ATCC 19434, E. gallinarumATCC 49608, E. casseliflavus ATCC 25788, and E. faecalis V583 CDC (26) were used as control strains during bacterial identification, PCRs, and DNA sequencing.
Strain information and structural data on vanBgene clustersa
Bacterial identification and susceptibility testing.The isolates were identified by positive Gram stain, absence of catalase, and presence of pyrrolidonylarylamidase activity as shown by the DrySlide PYR test (Difco, Detroit, Mich.). The strains were phenotypically identified to the species level by the ATB Rapid ID 32 STREP test (bioMérieux, Marcy l’Etoile, France), motility in modified Difco motility medium, and pigmentation after overnight growth on tryptic soy agar (11). Some of the strains were in addition identified by a slightly modified species-specificddl PCR (7). MICs for vancomycin and teicoplanin were determined by E test on PDM agar (PDM antibiotic sensitivity medium II; AB Biodisk, Solna, Sweden) with a final inoculum of about 5 × 105 CFU/ml.
PFGE typing.VanB-type VRE isolates from hospital patients in Norway (n = 3), Sweden (n = 1), the United Kingdom (n = 1), Germany (n = 3), and different locations in the United States (n = 9) were typed by SmaI (New England Biolabs, Beverly, Mass.) digestion and pulsed-field gel electrophoresis (PFGE) of chromosomal DNA as described by Murray et al. (21) with some modifications. Briefly, RNase One (0.5 U/ml; Promega, Madison, Wis.), lysozyme (1 mg/ml), proteinase K (4 mg/ml; Promega), SmaI (20 U/ml), a final agarose concentration of 0.8% in the agarose plugs, and a CHEF-DR III device (Bio-Rad, Hercules, Calif.) were used. The pulse time was increased from 1 to 35 s over 29 h at 200 V.
PCR.Preparation of bacterial DNAs was performed by using a Dynabeads DNA DIRECT kit (Dynal, Oslo, Norway) as described by Haaheim et al. (13). PCRs were performed in a GeneAmp PCR system (model 2400; Perkin-Elmer, Norwalk, Conn.). Primer sequences and target regions used for amplification in this study are listed in Table2. The vanB gene was amplified by the use of vanB1-specific (previously designatedvanB) primers (6) as well as a vanBconsensus PCR designed in our laboratory to amplify all vanBsubtypes. PCR conditions were as previously described (6). The vanB gene-positive strains were further analyzed by avanB long PCR (13) that covers 5,959 bp of the published vanB gene cluster from strain V583 (8) and by sequencing of the vanSB-vanYBintergenic region as well as partial vanB gene sequencing.E. faecium ATCC 19434 was used as a negative control andE. faecalis V583 CDC was used as a positive control in thevanB, vanB long, andvanSB-vanYB PCRs. ThevanSB-vanYB PCR was carried out with the Perkin-Elmer standard PCR reaction mix with GeneAmp PCR buffer. Amplification conditions were 94°C initially for 1 min; 94°C for 15 s, 60°C for 30 s, and 72°C for 1 min over 25 cycles; and a final 5-min extension period at 72°C.
PCR primers used to characterize the vanB gene cluster in VRE strains used in this study
RFLP analysis and DNA sequencing. BspHI/DraI (New England Biolabs)-digestedvanB long PCR products were analyzed on ethidium bromide-stained agarose gels. Both strands of the 484-bpvanB consensus primer amplicons and the 309-bpvanSB-vanYB amplicons were directly sequenced by using ABI Prism 377 (Perkin-Elmer) with the primers listed for these PCRs (Table 2) and dye-labeled terminators (Perkin-Elmer). The sequencing PCRs included cycles of 96°C for 1 min followed by 96°C for 10 s, 50°C for 5 s, and 60°C for 4 min over 25 cycles.
RESULTS
The results are summarized in Table 1. The 17 human VRE isolates were identified as 10 E. faecium strains, 6 E. faecalis strains, and 1 E. gallinarum strain. All isolates were shown to belong to different genome types bySmaI digestion and PFGE according to the criteria described by Tenover et al. (27).
The results from the vanB1-specific and vanBconsensus PCRs indicated the presence of 7 vanB1 isolates and 10 vanB2 or vanB3 isolates in this strain collection. The 484-bp vanB consensus primer amplicons were sequenced in order to confirm this assumption and to examine sequence heterogeneity within each subtype. The seven vanB1 strains showed sequence identity compared to the reference strain V583 (8) in the 406-bp readable sequence region. Nine isolates revealed a vanB2-specific sequence according to Gold et al. (12). In comparison to the original vanB2 gene sequence (12), one single point mutation was detected in TUH7-54 (position 5,499, T→G) and TUH7-15 (position 5,423, G→T). Two point mutations were detected in TUH4-54 (position 5,385, A→G; position 5,490, T→G) (data not shown). Strain TUH7-68, the originalvanB3 strain (22), was the only vanB3isolate studied.
A 309-bp amplicon (Fig. 1, lane 3) spanning the 175-bp vanSB-vanYBintergenic region and flanking coding sequences was bidirectionally sequenced in order to examine vanB intergenic sequence subtype specificity in a noncoding sequence. The 271-bp readable sequence corresponded to nucleotide positions 2,140 to 2,410 in the V583 vanB1 gene cluster (Fig.2). The sequence of the vanB1isolates was identical to the published sequence of strain V583 (GenBank accession no. U35369) with eight unique base pairs compared to the corresponding vanB2 andvanB3 intergenic regions. Eleven identical single point mutations and a 5-bp deletion were detected in thevanB2 strains in comparison to the vanB1 sequence (GenBank accession no. AF125544-AF125548 and AF125550 toAF125552). The vanB3 isolate (GenBank accession no.AF125553) had eight single point mutations common to thevanB2 subtype and only one unique base pair in thevanSB-vanYB intergenic region (Fig.2).
PCR amplification of thevanSB-vanYB intergenic region. Shown is a representative agarose electrophoresis gel of thevanSB-vanYB PCR products. Lane 1, φX174 DNA HaeIII digest (Promega); lane 2, isolate TUH7-15 amplicon of 1,098 bp; lane 3, typical 309-bp amplicon, represented by isolate TUH4-64. Molecular sizes shown to the left of the gel (in base pairs) refer to the φX174 DNA HaeIII digest.
Comparison of DNA sequences ofvanSB-vanYB amplicons. Shown is a comparison of vanSB-vanYB DNA sequences, represented by vanB1 isolate TUH4-64 (identical to the vanSB-vanYB region of the V583 vanB gene cluster), vanB2 isolate TUH2-18, and vanB3 isolate TUH7-68. Base pair differences between thevanB1 and the vanB2 and vanB3 strains are shown by single letters below the vanB1 cluster sequence. Gaps are shown by dashes. Nucleotide positions and stopvanSB and start vanYBpositions, according to the published vanB gene cluster sequence of reference strain V583, are shown above the aligned sequences.
The vanB long PCR, covering 5,959 bp of the published 6,436-bp vanB gene cluster (Fig.3), was positive in all isolates. RFLP analysis of the vanB long PCR products revealed identical patterns within the vanB1 and the vanB2 gene clusters, RFLP-1 and RFLP-2, respectively. RFLP-1 was in accordance with the vanB gene cluster sequence of the vanB1reference strain V583. The vanB2 strain TUH7-15 showed a unique RFLP-2 profile, RFLP-2* (see below), while the vanB3strain TUH7-68 displayed an RFLP-2 profile. Restriction analyses of thevanB long PCR amplicon from the vanB2 strain TUH2-18 by using BspHI and DraI separately (data not shown) showed that RFLP-2 was the result of an additionalBspHI site in the 1,086-bp fragment 3 (Fig. 3) covering position 450 to 1,535 in the V583 sequence. This BspHI site results in two bands of approximately 130 and 960 bp in thevanB2 and vanB3 isolates compared to the 1,086-bp fragment in the vanB1 strains (Fig.4, bottom). The additional 960-bp fragment in vanB2 and vanB3 strains is not visible in Fig. 4 (bottom) because this fragment runs superimposed on fragment 4 in the gel. However, both fragments can be visualized by restriction analyses with BspHI and DraI separately (data not shown).
Restriction pattern and PCR products in thevanB gene cluster. Restriction pattern and PCR products are deduced from the sequence of the reference strain V583. D,DraI; B, BspHI; 1 to 6,BspHI/DraI restriction fragments with decreasing sizes as follows: 1,491, 1,202, 1,086, 960, 654, and 566 bp, respectively. Open arrows represent coding sequences as labeled.
Analysis of vanB long PCR amplicons. (Top) Representative agarose electrophoresis gel of vanB long PCR amplicons. Lanes 1 and 6, 1-kb ladder (Life Technologies, Gaithersburg, Md.); lane 2, vanB2 isolate TUH2-18; lane 3,vanB3 isolate TUH7-68; lane 4, vanB2 isolate TUH7-15 with a 789-bp insertion; lane 5, vanB1 isolate TUH4-64. (Bottom) Restriction fragment analysis of vanB long PCR amplicons. Shown are BspHI/DraI-digestedvanB long PCR amplicons analyzed by agarose gel electrophoresis. Lanes 1 and 6, 1-kb ladder; lane 2, vanB2isolate TUH2-18 with RFLP-2; lane 3, vanB3 isolate TUH7-68 RFLP-2; lane 4, vanB2 isolate TUH7-15 with a 789-bp enlargement of fragment 4 (RFLP-2*); lane 5, vanB1 isolate TUH4-64 with RFLP-1. Molecular sizes shown to the left of each gel (in base pairs) refer to the 1-kb ladder.
The vanB long PCR amplicon from one U.S. isolate (TUH7-15) was larger than expected (Fig. 4, top, lane 4). ThisvanB2-type amplicon had an ∼800-bp enlargement of fragment 4 (RFLP-2*) covering the vanSB-vanYBregion of the gene cluster (Fig. 4, bottom). The enlargement of thevanSB-vanYB region was confirmed byvanSB-vanYB-specific PCR (Fig. 1, lane 2) and sequencing (data not shown). This vanB2 isolate had a 789-bp insertion in a vanB2-typevanSB-vanYB intergenic region containing a putative open reading frame. The first 147 amino acids showed 70% homology to the first 147 amino acids of an open reading frame in the Clostridium perfringens IS1469insertion element (3, 4) by comparison with known sequences performed by using the BLAST program.
Six of nine U.S. strains possessed the vanB1 gene, whereas 7 of 8 European strains possessed the vanB2 gene. The different strains showed various MICs of vancomycin, ranging from 32 to ≥256 μg/ml within the vanB1 group and from 12 to ≥256 μg/ml within the vanB2 group. MICs of teicoplanin were ≤1 μg/ml for all strains.
DISCUSSION
The presented molecular analysis of 17 genomically unrelated clinical VanB-type VRE from Europe and the United States reveals thatvanB gene clusters could be divided in three distinct subtypes: vanB1, vanB2, and vanB3. There was no correlation between vanB subtype and level of vancomycin resistance. The vanB1 and vanB2 gene clusters were demonstrated in both European and U.S. strains, while thevanB3 gene cluster was detected in only one U.S. strain. The organization of the vanB gene clusters, as shown by RFLP analysis of long PCR amplicons, is highly conserved within thevanB1 and vanB2 subtypes. All PCR-confirmedvanB1 gene isolates showed an RFLP-1 profile and identicalvanB1-subtype vanSB-vanYBintergenic sequences. Eight of the nine sequence-confirmedvanB2 isolates showed an RFLP-2 profile and a conservedvanB2-subtype vanSB-vanYBintergenic sequence. The vanB3 strain revealed avanB long PCR RFLP-2 profile and an intergenicvanSB-vanYB sequence with partial identity to both vanB1 and vanB2 sequences. One unique RFLP-2* profile was detected in the vanB2 strain TUH7-15 due to an insertion of 789 bp in thevanSB-vanYB area. Further characterization of this insertion element is in progress.
Our observations are consistent with earlier descriptions ofvanB gene sequence heterogeneity (12, 22). Gold and coworkers (12) proposed the vanB2 genotype based on a 3.6% base pair difference from the vanB1 ligase gene sequence of strain V583. Patel et al. (22) demonstrated sequence heterogeneity within the vanB2 gene and designated two clinical vanB VRE isolates with identical PFGE patterns to a vanB3 genotype. The 801 bp of the vanB3 gene (22) had a 3.6% base pair difference from the publishedvanB2 gene sequence (12) and a 5% base pair difference from the V583 vanB1 gene (8). ThevanB consensus primers designed in our laboratory are able to direct amplification of vanB1, vanB2, andvanB3 genes under stringent PCR conditions. ThevanB1-specific primers described by Clark and coworkers (6) did not direct amplification of vanB2 andvanB3 genes. They could therefore be used to distinguish thevanB1 gene from vanB2 and vanB3 genes, as shown in this study. The combined use of thevanB1-specific and the vanB consensus primers does not distinguish between vanB2 and vanB3subtypes. However, sequencing of the vanB consensus primer target revealed vanB2 and vanB3 differences in the 10 vanB1 PCR-negative strains. Six vanB2strains had a DNA sequence identical to that of the previously described vanB2 ligase gene (12). Single point mutations were detected in three vanB2 strains. The base pair transversion in TUH7-15 has been described previously (22). These strains should be classified as vanB2subtype since they only differed from the previously describedvanB2 gene by one or two nucleotides. In comparison, the TUH7-68 vanB3 strain showed 12 base pair substitutions in the corresponding part of the vanB ligase gene as described previously by Patel and coworkers (22).
The molecular heterogeneity of the vanB gene clusters has implications for the selection of diagnostic primers used to examine VanB-type resistance, as the primers must ensure the detection of allvanB subtypes. Our vanB consensus primers direct amplification of vanB1, vanB2, andvanB3 genes, as shown in this study.
The original arguments for dividing the vanB ligase gene into three subtypes were based on sequence differences and the stability of these differences, at least in vanB1 andvanB2 ligase genes. Examination of sequence differences between the vanB subtypes (22) reveals that thevanB1, vanB2, and vanB3 genes have 22, 6 to 9, and 19 conserved unique nucleotides, respectively. The present study suggests that the nucleotide sequences in thevanSB-vanYB intergenic region of thevanB gene cluster also display a correspondingvanB-subtype specifity (Fig. 2). (The vanB1subtype has eight unique base pairs, the vanB2 subtype has a unique 5-bp deletion and three unique substitutions, and thevanB3 type strain has one unique base pair in this region. The vanB1 subtype has also lost one BspHI restriction site in the vanRB-vanSBgene area compared to the vanB2 and vanB3subtypes, as shown by vanB long PCR-RFLP analysis.) The observed nucleotide sequence differences do not allow any conclusions to be made with regard to which vanB subtype should be considered the ancestral vanB gene cluster. However, thevanB2 ligase gene sequence seems to be less conserved than the vanB1 ligase gene (reference 22 and this study), indicating that the vanB2 gene cluster might be older than the vanB1 cluster in evolutionary terms. More sequence data are needed to support this observation. Since thevanB3-type gene cluster has been detected in only one strain, we do not know anything about the spread and sequence stability within this vanB subtype.
The vanB long PCR-RFLP analysis provides structural information on the vanB gene cluster that might be of interest in molecular epidemiological studies. The TUH7-15 RFLP-2* profile seems to be the result of a unique genetic event and is an example of the potential usefulness of such analysis.
The low MICs of vancomycin in some of the vanB1 andvanB2 strains are of clinical importance because they are difficult to detect by standard disk diffusion susceptibility testing. The Norwegian and Swedish strains (n = 4) showed MICs of vancomycin ranging from 12 to 32 μg/ml as determined by the E-test method. This could reflect the restricted use of glycopeptide antibiotics in these countries. It is difficult to assess how much thevanB gene contributes to the MIC (32 μg/ml) for the Norwegian E. gallinarum strain TUH7-16, as this strain also harbors a vanC1 gene as demonstrated by PCR (data not shown). Analyses of vanB or vanC1 gene expression have not been performed on this strain.
Our results have confirmed and extended earlier descriptions ofvanB gene heterogeneity (12, 22). These observations are of importance when considering reservoirs and dissemination of VanB-type VRE. The sequence homology within thevanB1 and the vanB2 subtypes in genomically unrelated VRE strains indicates horizontal transmission of thevanB gene cluster as a major mode of dissemination of VanB-type glycopeptide resistance in enterococci. The high structural stability in the vanB gene clusters as shown by RFLP of long PCR amplicons indicates that the gene clusters have evolved from a common origin. The stable sequence differences between thevanB subtypes described in the present work and by Patel and coworkers (22) suggest a long-term separate evolution which might have occurred during selection in different ecological niches.
The sequence diversity in vanB resistance determinants is in contrast to the reported DNA sequence homogeneity in thevanA gene clusters (17, 22, 29). However, the Tn1546 or Tn1546-like elements conferring VanA-type resistance display structural heterogeneity (13-15, 17, 29) in contrast to the vanB gene clusters as shown in this study. The structural diversity in Tn1546 elements seems to be caused by deletions or insertions which may have occurred during single recombination events (14, 15, 17, 29). These rearrangements may have taken place recently. Several European studies have revealed a large environmental reservoir (17, 19, 20, 29) of VanA-type glycopeptide resistance determinants as well as VanA-type VRE in outpatients (18, 19, 28). A possible spread of VanA-type VRE through the food chain has been suggested (19, 28). To our knowledge, VanB-type VRE have only been detected in a hospital patient setting. The finding of at least three subtypes of thevanB gene cluster as described in the present work should encourage a search for different environmental reservoirs ofvanB resistance determinants.
ACKNOWLEDGMENTS
This work was supported by grants from the Norwegian Research Council, the Scandinavian Society for Antimicrobial Chemotherapy, and the Odd Berg Foundation.
We thank P. R. Chadwick of North Manchester General Hospital, Manchester, United Kingdom, S. Harthug and A. Digranes of Haukeland University Hospital, Bergen, Norway; I. Klare of the Robert Koch Institute, Wernigerode, Germany; E. B. Myhre of Lund University Hospital, Lund, Sweden; M. A. Pfaller and S. A. Marshall of the University of Iowa College of Medicine, Iowa City; and R. Patel of the Mayo Clinic and Foundation, Rochester, Minn.) for providing strains. We also thank Bjørg C. Haldorsen for excellent technical assistance.
FOOTNOTES
- Received 3 November 1998.
- Returned for modification 7 January 1999.
- Accepted 3 March 1999.
- Copyright © 1999 American Society for Microbiology
